News | April 04, 2011

Clinical Cancer Research Programs to Merge

April 4, 2011 – The American College of Radiology's Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG), National Cancer Institute (NCI) Clinical Trials Cooperative Group members, have announced their intent to merge their clinical cancer research programs.

The groups plan to form an alliance that combines their complementary strengths. The new organization will include three areas of research emphasis: early detection and diagnosis of cancer; biomarker-driven Phase II and Phase III therapeutic studies for multiple cancer types and stages; and genetic, molecular and imaging marker research to predict and monitor treatment response.

ECOG and ACRIN's individual programs have significantly contributed to improved clinical care. The new alliance will bring together the organizations' unique capabilities to build a program with expanded scientific scope and depth of expertise. ECOG has strengths in performing large-scale trials with molecular endpoints in major diseases. The results of these studies have changed the treatment of cancer patients and helped to individualize that therapy. ACRIN's clinical trials encompass the full range of medical imaging research, from landmark cancer screening trials to early phase trials evaluating imaging biomarkers and novel imaging technologies. While maintaining these areas of separate expertise, the alliance will press the tailoring of therapy to the individual patient's tumor, and accelerate the integration of biological advances into clinical practice.

"This partnership offers the research community a new sphere of engagement," said Robert L. Comis, M.D., chair of ECOG. "It will greatly enhance our position in the public and private sectors to perform biomarker-driven studies and develop more innovative clinical trial designs. ACRIN has an exceptional imaging research program and IT infrastructure, which can be applied to compile and store not only radiologic images, but also, relevant laboratory based images. Our modality and disease committees will have the opportunity to become involved in the development of cutting edge early detection and diagnostic studies, and ACRIN investigators will benefit from being fully integrated into our therapeutically oriented programs."

"We are excited by the ECOG partnership opportunity to develop a unique multidisciplinary organization positioned to study the entire cancer care path from early detection through management of advanced disease," says Mitchell D. Schnall, M.D., Ph.D., ACRIN Network chair. "We will leverage the complementary scientific expertise of each group to develop multidisciplinary scientific committees to address each of the three emphasis areas for which there will be immediate opportunities for interaction and collaboration. The integration of ECOG and ACRIN patient advocacy and clinical research associate committees will bring together an impressive knowledge base representing the patient perspective and participant recruitment best practices – a significant support for getting the research done."

"Clinical research has been an important component of the American College of Radiology (ACR) for over 40 years," said Harvey L. Neiman, M.D., FACR, the ACR's CEO. "I commend the decision to bring together the extensive resources of ACRIN and ECOG to carry out clinical research that combined has even greater potential to bring forth new scientific discoveries to detect cancer earlier and to improve the care and quality of life of cancer patients."

Transition planning is underway, and group leaders are developing the business, administrative and scientific structures. The new organization will sustain its research portfolio with public and private support. Relative to public funding, the NCI announced last November that it will reorganize its Cooperative Group program to support up to four adult cooperative groups, and will issue a new Funding Opportunity Announcement (FOA) in Spring 2012. The new organization will respond on behalf of ECOG and ACRIN.

For more information: www.acrin.org, www.ecog.org

Related Content

 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one hold out who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one holdout who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

Feature | Nuclear Imaging | August 30, 2019 | Dave Fornell, Editor
In a surprising move, the National Institute for Radioelements (IRE) has applied for a new license to export highly e
University of Alabama at Birmingham Leading Production of Theranostic Radioisotope

Image courtesy of the University of Alabama at Birmingham

News | Radiopharmaceuticals and Tracers | August 29, 2019
The University of Alabama at Birmingham, in conjunction with researchers at the University of Wisconsin and Argonne...
ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy
News | Radiopharmaceuticals and Tracers | July 26, 2019
NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...